drugset / Trial / NCT02970539
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers
NaSequentialOpen-labelTreatment
Summary
This is a nonrandomized, open-label, single group assignment, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing regimen of Oraxol in combination with ramucirumab.
Timeline
- Start
- 2016-12-08
- Primary completion
- 2019-03-27
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HM30181AK | Unknown | — | Oral |
| Subject | Paclitaxel | Small molecule | — | Oral |
| Background | Ramucirumab | Monoclonal antibody | — | Intravenous |